AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04642768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoneAid Ketone Ester
Description: Commercially available ketone supplement
Study NCT04642768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Commercially available maltodextrin supplement
Study NCT06051916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: residual urine
Description: The study includes two group, A and B. Se previously
Study NCT05171101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAVEN
Description: The MAVEN education training program will be comprised of a 7-day virtual summer institute and a 7-day second virtual summer institute focused on respect-based leadership, senior scientist career planning, evidence-based mentoring, organizational culture problem solving, interdisciplinary team collaboration and inclusivity, effective science thought leadership, and public engagement. These summer institutes will be comprised of didactics, discussions, and interactive individual and team-based activities. Between the institutes there will be 10 months of mentorship, networking, and conduct of institutional change projects.
Study NCT04847960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioGaia Probiotic Lozenges
Description: BioGaia Prodentis lozenges is a food supplement for oral health that contains patented lactic acid bacteria Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) Prodentis (a combination of strains of L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) which helps good microorganisms maintain natural balance in the mouth. This product is safe for daily use and this product can be used during pregnancy and breastfeeding. The ingredients of this product are: bulking agent (isomalt), L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289, fully hydrogenated palm oil, peppermint flavoring, menthol flavoring, peppermint oil and sweetener (sucralose). One candy contains a minimum of 200 million live L. reuteri Prodentis. Net weight per candy is 800 mg. Excessive consumption can have a laxative effect due to the sweetener content in the product. This product has obtained a distribution permit in Indonesia with a BPOM number: SI194510521 with the name Probiotic Prodentis (Pro-D).
Study NCT03919188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air temperature control (ATC)
Description: Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
Study NCT03919188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin servocontrol (SSC)
Description: Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
Study NCT04651907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point
Study NCT04651907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: minimal acupuncture
Description: The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
Study NCT05080998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CxBladder Monitor
Description: CxBladder Monitor (CxbM) is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
Study NCT04632433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg every 3 weeks
Study NCT04580485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB106385
Description: INCB106385 will be administered orally QD
Study NCT04580485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: INCMGA0012 will be administered IV once every 4 weeks (Q4W)
Study NCT05330286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: oral solution
Study NCT05330286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: Oral solution
Study NCT05330286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: Oral solution given in fasted state
Study NCT05330286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: Oral solution given in fed state
Study NCT06205277 — intervention group
Intervention type: PROCEDURE
Intervention: Second TURBt
Description: Second TURBt for pT1 NMIBC as per current EAU Guidelines.
Study NCT05711966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator for High-frequency Oscillatory Ventilation (HFOV)
Description: This device will be used to perform an HFOV recruitment maneuver before surfactant administration
Study NCT05711966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Less invasive surfactant administration (LISA)
Description: SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
Study NCT06053502 — intervention group
Intervention type: OTHER
Intervention: filtering facepiece respirator
Description: Graded exercise test with filtering facepiece respirator
Study NCT05410184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses group
Description: Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device
Study NCT05410184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mural curtain group
Description: the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
Study NCT06277427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRG-1801 （CAR-T against BCMA）
Description: Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
Study NCT06524843 — intervention group
Intervention type: OTHER
Intervention: Analysis
Description: Analysis and review of imaging and clinical data
Study NCT05684172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
Study NCT05684172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: endovascular thrombectomy alone
Description: Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
Study NCT05684172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy alone
Description: Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
Study NCT05855811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab should initiated within 6 months after the end of treatment for FPC.
Study NCT04396418 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Randomization between two groups at site level. One cluster with education and one without.
Study NCT04396418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Randomization between two groups at site level. One cluster with education and one without.
Study NCT04683640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GABA
Description: Daily oral GABA for 4 weeks
Study NCT04683640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral Placebo for 4 weeks
Study NCT05024227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: nursing education interventions (including e-health platform assistance)
Description: Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
Study NCT06154486 — intervention group
Intervention type: DRUG
Intervention: semaglutide use
Description: patient using semaglutide for at least 7 days
Study NCT04579133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID OR 200 mg BID (if glomerular filtration rate \[GFR\] 31 to 50 mL/min)
Study NCT04579133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV
Study NCT05938231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass Stent System
Description: Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.
Study NCT05938231 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Intervention
Description: The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
Study NCT05938231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
Study NCT05902923 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular intervention
Description: endovascular intervention
Study NCT04294563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut Protein Powder
Description: Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
Study NCT04294563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care by Surgeon and Physical Therapist
Description: Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
Study NCT04294563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care by Surgeon and Physical Therapist
Description: Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
Study NCT05300074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
Study NCT05277129 — intervention group
Intervention type: OTHER
Intervention: Analysis of post-stroke immune responses
Description: Analysis of immune responses in peripheral blood
Study NCT06200064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-stretching exercise group
Description: Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
Study NCT06200064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-isometric relaxation exercise group
Description: The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity.
Study NCT06135077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-PRF alone
Description: T-PRF is the material to be tested in this study as an alternative to classical bone graft
Study NCT06135077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T-PRF/Xenograft
Description: One part of T-PRF will be divided into minute pieces to be mixed with xenograft
Study NCT01188213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM)
Study NCT04742322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Lactis CCT7858
Description: Probiotic B Lactis
Study NCT04742322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin
Study NCT06394440 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Self-Adhesive Bulkfill Composite (Surefil One)
Description: It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.
Study NCT06394440 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Self-Adhesive Bulkfill Composite (Surefil One)
Description: It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.
Study NCT05751291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve.
Study NCT05509933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: budesonide starting day 5 after transplant
Study NCT05601791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
Study NCT05601791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Laser Disc Decompression
Description: Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
Study NCT05380492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOY-101
Description: Intravitreal injection of VOY-101
Study NCT06087016 — intervention group
Intervention type: OTHER
Intervention: Urine vibrational analysis
Description: Urine vibrational analysis
Study NCT04589754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sintilimab plus chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
Study NCT04589754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
Study NCT04589754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adriamycin-based chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
Study NCT04589754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin-based chemotherapy
Description: AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
Study NCT05924685 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccination
Description: Vaccination
Study NCT05866887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep ALL Night
Description: Sleep intervention program comprised of a sleep action plan tool and interactive psychoeducation website.
Study NCT04822623 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI examination
Study NCT06266819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.
Study NCT05291767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: participants will consume a high fat (intervention) or high carbohydrate (control) meal.
Study NCT05291767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
Study NCT06251609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone 2 MG
Description: The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine. When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The naloxone will be administered following the first dose of epinephrine. The control is saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. They will be identical in appearance to the naloxone syringes.
Study NCT06251609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 2ml
Description: Placebo
Study NCT05127369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental pulp mesenchymal cell injection
Description: Dental pulp mesenchymal cell injection was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
Study NCT05127369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dental pulp mesenchymal cell vehicle
Description: Dental pulp mesenchymal cell vehicle was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
Study NCT05127369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine hydrochloride capsule
Description: fluoxetine hydrochloride capsule
Study NCT05127369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine hydrochloride capsule
Description: fluoxetine hydrochloride capsule
Study NCT04916522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg once daily
Study NCT04916522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT05394376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Level of noise and environment (public vs private) while taking blood pressure measurement
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
Study NCT05647850 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05049278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: * Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)
Study NCT05049278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: * Continuous drug: phenylephrine 10mg \* 5@ + D5W 200 mL (250 μg/mL)~* Range: 0.42 \~ 1.26 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)
Study NCT05427903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Ice packs application for 5 minutes after IANB injection
Study NCT05427903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Ice packs application for 5 minutes after IANB injection